Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Liabilities from Discontinued Operations (2020)

Lexaria Bioscience's Liabilities from Discontinued Operations history spans 1 years, with the latest figure at 250.0 for Q3 2020.

  • Quarterly results put Liabilities from Discontinued Operations at 250.0 for Q3 2020, changed N/A from a year ago — trailing twelve months through Aug 2020 was 250.0 (changed N/A YoY), and the annual figure for FY2020 was 250.0, changed.
  • Liabilities from Discontinued Operations for Q3 2020 was 250.0 at Lexaria Bioscience, roughly flat from 250.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 250.0 in Q2 2020 to a low of 250.0 in Q2 2020.